Feola S

Harnessing T cell exhaustion and trogocytosis to isolate patient-derived tumor-specific TCR.

Manfredi F, Stasi L, Buonanno S, ..., Bonini C, Ruggiero E

Sci Adv 9 (48) eadg8014 [2023-12-00; online 2023-12-01]

Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors.

Chiaro J, Antignani G, Feola S, ..., Lehtiö J, Cerullo V

Nat Commun 14 (1) 7056 [2023-11-03; online 2023-11-03]

Development of mesothelioma-specific oncolytic vaccine exploiting immunopeptidomic analysis of murine and human tumors

Chiaro J, Antignani G, Feola S, ..., Lehtiö J, Cerullo V

- - (-) - [2022-11-08; online 2022-11-08]

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.

Feola S, Chiaro J, Martins B, ..., Lehtiö J, Cerullo V

Elife 11 (-) - [2022-03-22; online 2022-03-22]

Author response: A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines

Feola S, Chiaro J, Martins B, ..., Lehtiö J, Cerullo V

- - (-) - [2022-02-22; online 2022-02-22]

PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification.

Feola S, Haapala M, Peltonen K, ..., Sikanen TM, Cerullo V

ACS Nano 15 (10) 15992-16010 [2021-10-26; online 2021-10-04]

Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy.

Peltonen K, Feola S, Umer HM, ..., Lehtiö J, Cerullo V

Cancers (Basel) 13 (14) - [2021-07-07; online 2021-07-07]

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines

Feola S, Chiaro J, Martins B, ..., Lehtiö J, Cerullo V

- - (-) - [2021-06-09; online 2021-06-09]